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Atherogenic Lipoprotein Determinants of Cardiovascular Disease and
Residual Risk Among Individuals With Low Low-Density Lipoprotein
Cholesterol
Patrick R. Lawler, MD, MPH; Akintunde O. Akinkuolie, MBBS, MPH; Audrey Y. Chu, PhD; Svati H. Shah, MD, MHS;
William E. Kraus, MD; Damian Craig, MSc; Latha Padmanabhan, MSc; Robert J. Glynn, ScD; Paul M Ridker, MD, MPH;
Daniel I. Chasman, PhD; Samia Mora, MD, MHS
Background-—Levels of LDL (low-density lipoprotein) cholesterol in the population are declining, and increasing attention is being
focused on residual lipid-related pathways of atherosclerotic cardiovascular disease risk beyond LDL cholesterol. Among
individuals with low (<130 mg/dL) LDL cholesterol, we undertook detailed proﬁling of circulating atherogenic lipoproteins in
relation to incident cardiovascular disease in 2 populations.
Methods and Results-—We performed proton nuclear magnetic resonance spectroscopy to quantify concentrations of LDL and
VLDL (very low-density lipoprotein) particle subclasses in 11 984 JUPITER trial participants (NCT00239681). Adjusted Cox models
examined cardiovascular disease risk associated with lipoprotein measures according to treatment allocation. Risk (adjusted
hazard ratio [95%CI] per SD increment) among placebo-allocated participants was associated with total LDL particles (1.19 [1.02,
1.38]) and total VLDL particles (1.21 [1.04, 1.41]), as well as apolipoprotein B, non–high-density lipoprotein cholesterol, and
triglycerides, but not LDL-c. Rosuvastatin reduced LDL measures but had variable effects on triglyceride and VLDL measures. On-
statin levels of the smallest VLDL particle subclass were associated with a 68% per-SD (adjusted hazard ratio 1.68 [1.28, 2.22])
increase in residual risk—this risk was related to VLDL cholesterol and not triglyceride or larger VLDL particles. There was
evidence that residual risk prediction during statin therapy could be signiﬁcantly improved through the inclusion of key VLDL
measures (Harrell C-index 0.780 versus 0.712; P<0.0001). In an independent, prospective cohort of 4721 individuals referred for
cardiac catheterization (CATHGEN), similar patterns of lipoprotein-related risk were observed.
Conclusions-—Atherogenic lipoprotein particle concentrations were associated with cardiovascular disease risk when LDL
cholesterol was low. VLDL lipoproteins, particularly the smallest remnant subclass, may represent unused targets for risk
prediction and potential therapeutic intervention for reducing residual risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00239681. ( J Am Heart Assoc. 2017;6:
e005549. DOI: 10.1161/JAHA.117.005549.)
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P opulation levels of LDL-c (low-density lipoprotein choles-terol) are declining with increasing adherence to healthy
lifestyle and pharmacologic interventions.1,2 However, cardio-
vascular disease (CVD) events remain prevalent among
individuals with low or normal LDL-c, both pretreatment and
during high-intensity statin therapy,3 a phenomenon referred
to as residual risk. In parallel, as population levels of LDL-c
have declined over recent years, studies have demonstrated
time-dependent changes in the composition and morphology
of human atherosclerotic plaque,4 suggesting shifting mech-
anisms of atherogenesis and plaque disruption amid this
changing risk factor exposure and changing epidemiology of
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CVD.5 Numerous studies have suggested that LDL-c does not
account for all of the risk conferred by atherogenic plasma
lipids and the insulating lipid and protein assemblies that
transport them in the bloodstream, lipoproteins,6,7 and thus, it
is possible that residual lipid and lipoprotein risk pathways or
markers that were previously eclipsed in signiﬁcance by LDL-c
are likely to emerge as increasingly important determinants of
CVD.
To understand the residual markers of lipid- and lipopro-
tein-related risk in the era of LDL-c reduction and to forecast
the emergence of such alternate risk pathways, we examined
populations of individuals with low (<130 mg/dL) LDL-c with
advanced lipoprotein proﬁling. Detailed lipoprotein phenotyp-
ing by proton nuclear magnetic resonance (1H NMR) spec-
troscopy can quantify concentrations, subclass distributions,
composition, and size of atherogenic LDL particles (LDL-p)
and very low-density lipoprotein particles (VLDL-p) in circula-
tion.8,9 Accordingly, this study was designed (Figure 1) to (1)
identify potential NMR-measured lipoproteins associated with
incident CVD risk in a population of individuals with naturally
normal or low LDL-c, (2) understand the changes in the
lipoprotein milieu accompanying high-intensity statin therapy,
and (3) identify lipoprotein subclasses associated with on-
statin risk of CVD events despite achieved low levels of LDL-c.
We sought to extend the ﬁndings by examining an indepen-
dent, diverse cohort of individuals referred for cardiac
catheterization (CATHGEN).
Material and Methods
Study Design and Population
The primary study population is derived from a primary-
prevention randomized controlled clinical trial of rosuvastatin
20 mg versus placebo (Justiﬁcation for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin,
JUPITER; NCT00239681).10 The JUPITER trial randomized
individuals (women ≥60 years, men ≥50 years) without prior
history of CVD or diabetes mellitus, all of whom had LDL-c
<130 mg/dL, high-sensitivity C-reactive protein (hsCRP
≥2.0 mg/L), and triglycerides ≤500 mg/dL. The relative risk
reduction for the primary incident CVD end point was 44%.10
We performed 1H NMR lipoprotein measurements on fasting
blood samples from11 984participants (ofwhom9222alsohad
1-year samples) who consented to and provided additional blood
collection with sufﬁcient plasma available. In the placebo-
allocated arm, baseline lipoprotein measurements were used to
identify lipoproteins associated with risk of incident CVD in
untreated individuals. In the statin-allocated arm, (1) change in
lipoprotein measurements from baseline to 12 months after
randomization was used to understand the effects of statin
therapy on lipoprotein subfractions, and (2) on-statin (12 month)
lipoprotein measurements were used to identify lipoproteins
associated with residual on-statin risk of incident CVD.
Laboratory Analysis
Standard lipid measurements were performed on fasting sam-
ples by a central laboratory.11 LDL-c was calculated by the
Friedewald equation (total cholesterol minus HDL-c minus
triglycerides/5) when triglycerides were <400 mg/dL, and
measured by ultracentrifugation when triglycerides were
≥400 mg/dL. Triglycerides were measured using a colorimetric
assay. Measurement of apolipoproteins B (apoB) was via
immunonephelometry byusing aBehring nephelometric assay.12
After trial completion, 1H NMR spectroscopy (400 MHz)
LipoProﬁle III measurements were performed on stored
plasma samples by LipoScience, Inc (Raleigh, NC; now
LabCorp). NMR was used to quantify total LDL-p and its
lipoprotein subclass concentrations (small and large LDL-p,
and intermediate density lipoprotein [IDL-p]), and average LDL
Clinical Perspective
What Is New?
• Among a population intended to represent the growing
number of individuals with low low-density lipoprotein
cholesterol, atherogenic lipoprotein particle concentrations
(low-density lipoprotein and very low-density lipoprotein
particles) were markers of residual atherosclerotic cardio-
vascular disease risk.
• Among individuals with the lowest low-density lipoprotein
cholesterol on statin, the smallest subclass of very low-
density lipoprotein was strongly associated with residual
risk.
• This risk was related to the cholesterol carried in small very
low-density lipoprotein, and not triglyceride.
• Similar patterns were observed in an independent, diverse
population of individuals referred for cardiac catheterization
at a single center.
What Are the Clinical Implications?
• Species of triglyceride-rich lipoproteins (very low-density
lipoproteins) may represent unused clinical targets for risk
prediction and potential therapeutic intervention in the
prevention of atherosclerotic cardiovascular disease, par-
ticularly among individuals with low-density lipoprotein
cholesterol reduction on statin.
• Triglyceride level may incompletely reﬂect risk differentially
related to triglyceride-rich lipoprotein subclasses.
• Detailed phenotyping of the circulating lipid and lipoprotein
milieu could improve risk assessment, as well as advance
the evaluation of emerging therapies to prevent cardiovas-
cular disease.
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Table 1. Baseline Characteristics in the Study Sample Vs the Original JUPITER Cohort
Characteristic
Current Study (N=11 984) JUPITER (N=17 802) Not in Current Study (N=5818)
Median (IQR) or N (%) Median (IQR) or N (%) Median (IQR) or N (%)
Age 66 (60, 71) 66 (60, 71) 66 (61, 71)
Women 4360 (36) 6801 (38.2) 2411 (42)
Rosuvastatin 5934 (50) 8901 (50.0) 2967 (51)
Race/ethnicity
White 9894 (82.6) 12 683 (71.3) 2789 (48)
Black 746 (6.2) 2224 (12.5) 1478 (25)
Asian 178 (1.5) 283 (1.6) 105 (1.8)
Hispanic 1076 (9.0) 2261 (12.7) 1185 (20)
Other/unknown 88 (0.7) 349 (2.0) 261 (5)
Body-mass index, kg/m2 28.4 (25.5, 32.0) 28.4 (25.3, 32.0) 28.0 (24.7, 32.0)
Hypertension, % 6719 (56.1) 10 208 (57) 3489 (60)
Systolic blood pressure, mm Hg 134 (124, 146) 134 (124, 145) 134 (125, 145)
Diastolic blood pressure, mm Hg 80 (75, 86) 80 (75, 87) 80 (76, 88)
Current smoker 1757 (14.7) 2820 (15.9) 1063 (18)
Family history of premature CAD 1527 (12.8) 2045 (11.5) 518 (9.0)
Glucose, mg/dL 95 (88, 102) 94 (88, 102) 93 (86, 101)
hsCRP, mg/L 4.10 (2.75, 6.70) 4.25 (2.85, 7.10) 4.70 (2.95, 8.05)
LDL cholesterol, mg/dL 109 (95, 119.5) 108 (94, 119) 106 (91, 118)
Non-HDL cholesterol, mg/dL 135 (120, 147) 134 (118, 147) 132 (114, 146)
Apolipoprotein B, mg/dL 109 (97, 122) 109 (95, 122) 108 (93, 122)
Triglycerides, mg/dL 119 (87, 169) 118 (85, 169) 116 (83, 169)
HDL cholesterol, mg/dL 49 (41, 60) 49 (40, 60) 48 (40, 59)
CAD indicates coronary artery disease; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; JUPITER, Justiﬁcation for the Use of Statins in Prevention: an Intervention Trial;
LDL-c, low-density lipoprotein cholesterol; LDL-p, low density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; VLDL-c, very low
density lipoprotein cholesterol; VLDL-p, very low density lipoprotein particle concentration.
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Figure 1. Overview of the study: impetus for the study, study populations, lipoprotein measures, lipoprotein proﬁling, and results. CATHGEN
indicates CATHeterization GENetics biorepository; CVD, cardiovascular disease; JUPITER, Justiﬁcation for the Use of Statins in Prevention: an
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particle size. Total VLDL-p and its subclasses (small, medium,
and large) were quantiﬁed, as well the concentration of VLDL
and chylomicron triglyceride (VLDL/CM TG) and cholesterol
(VLDL-c). We also examined formulaic remnant cholesterol,
which was calculated as total cholesterol minus HDL-c minus
LDL-c. (Calculating remnant cholesterol as triglycerides
divided by 513 yielded nearly identical results, as expected,
based on use of the Friedewald equation.)
Outcomes
The primary outcome was the trial primary end point, a
composite incident CVD end point deﬁned as the occurrence of
either myocardial infarction, stroke, hospitalization for unstable
angina, arterial revascularization, or cardiovascular death.10 An
expanded end point of CVD or all-cause mortality was also
examined, consistent with prior JUPITER biomarker analyses.14
Extension to Other Populations
We sought to extend the JUPITER ﬁndings in an independent,
prospective cohort encompassing a diverse population
referred for cardiac catheterization at Duke University from
2001 to 2010 (CATHGEN; dmpi.duke.edu/cathgen).15 As in
JUPITER, we focused on individuals with LDL-c <130 mg/dL
and TG <500 mg/dL (N=2149 individuals). (The hsCRP was
not routinely measured.) We also examined the subset of
participants with conﬁrmed statin prescription (N=833) as well
as, more broadly, risks among all comers in the cohort without
LDL-c stratiﬁcation. Lipoprotein subclasses were measured
using the same NMR assay as in JUPITER. Fatal or nonfatal
myocardial infarction was the primary outcome in this mixed
population of individuals both with and without established
CVD. Cox models included all covariables used in the JUPITER
analyses except for hsCRP, which was not routinely measured.
Statistical Analyses
Medians (25th, 75th percentiles) were displayed for contin-
uous variables. Lipoprotein change was evaluated using the
Wilcoxon signed-rank test. Exposure time was calculated as
the time from randomization to end-point occurrence or
censoring (the latter including censoring at time of noncar-
diovascular mortality). Cox proportional hazards models were
used to calculate hazard ratios and 95% CIs for CVD in
relation to per-SD increments in measures. Nonnormally
distributed data were (natural) log transformed. Additionally,
risk was examined across lipoprotein tertiles. Models were
adjusted for age, sex, race, smoking, family history of
premature coronary disease, body-mass index, systolic blood
pressure, fasting glucose, and hsCRP. Sensitivity analyses
mutually adjusting for other NMR lipoprotein subclasses were
performed,16 as well as adjusting for HDL-c. Additionally, a
minority of individuals in these analyses had events before on-
treatment NMR measurement; however, the majority of
events occurred after measurement, and in sensitivity anal-
yses beginning the follow-up at time of NMR measurement,
the results were not appreciably different, although with less
power some associations were no longer signiﬁcant. We
assessed predictive model performance by assessing the
change in Harrell C-index (and quantitatively with the
likelihood ratio test) for 2 hierarchically nested models
predicting primary CVD events: (1) a model that incorporated
all variables from the Cox model (above) plus standard lipids
(LDL-c, HDL-c, and triglyceride), and (2) a full model including
all variables from model 1 plus all of the atherogenic NMR
Large LDL-p (36.5%)
Small LDL-p (48.0%)
IDL-p (12.3%)
Medium VLDL-p (0.9%)
Small VLDL-p (2.1%)
Large VLDL-p (0.2%)
Figure 2. Schematic representation of the median proportion of atherogenic (LDL
and VLDL) lipoprotein subclasses (median subclass particle concentration divided by
median total LDL+VLDL particle concentration measured with NMR) at baseline in
fasting samples in the rosuvastatin arm pre-treatment. IDL-p indicates intermediate
density lipoprotein particle concentration; LDL-p, low density lipoprotein particle
concentration; NMR, nuclear magnetic resonance; VLDL-p, very low density
lipoprotein particle concentration.
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Table 3. Baseline, Follow-Up, and Change in Lipid and Lipoprotein Measures in the Placebo and Rosuvastatin Groups*
Baseline Year 1† Absolute Change‡ % Change
Lipids and apolipoproteins, mg/dL
LDL-c
Placebo 110 (96, 119) 111 (96, 125) 3 (8, 15) 2.7 (7.4, 14.4)
Rosuvastatin 109 (96, 120) 55 (44, 71) 51 (65, 31) 49.0 (58.2, 32.8)
Non-HDL-c
Placebo 135 (121, 147) 138 (121, 154) 3 (9, 16) 2.4 (6.4, 12.1)
Rosuvastatin 135 (121, 148) 77 (65, 96) 56 (71, 34) 42.7 (51.1, 27.7)
Apolipoprotein B
Placebo 110 (97, 122) 106 (93, 119) 3 (13, 7) 2.9 (11.6, 6.3)
Rosuvastatin 110 (97, 123) 66 (57, 81) 42 (54, 27) 39.4 (47.6, 26.7)
Triglycerides
Placebo 119 (88, 168) 120 (90, 167) 2 (24, 25) 1.3 (18.4, 24.7)
Rosuvastatin 120 (88, 171) 102 (77, 139) 17 (48, 5) 15.5 (32.8, 5.26)
NMR lipoproteins
LDL size, nm diameter
Placebo 21 (20.5, 21.4) 21 (20.5, 21.3) 0.0 (0.3, 0.3) 0.0 (1.5, 1.4)
Rosuvastatin 21 (20.5, 21.4) 20.6 (20.2, 21.0) 0.3 (0.8, 0.1) 1.5 (3.7, 0.5)
LDL-p by subclass, nmol/L
Total
Placebo 1282 (1089, 1476) 1224 (1044, 1427) 52 (197, 95) 4.2 (14.7, 8.3)
Rosuvastatin 1274 (1101, 1484) 771 (633, 964) 487 (674, 284) 39.6 (49.4, 24.7)
Large
Placebo 457 (307, 602) 438 (276, 586) 20 (143, 104) 5.3 (31.0, 27.4)
Rosuvastatin 462 (304, 600) 174 (93, 306) 237 (391, 71) 57.5 (77, 24.4)
Small
Placebo 612 (448, 841) 596 (440, 829) 14 (159, 127) 2.6 (22.9, 23.2)
Rosuvastatin 608 (446, 849) 494 (374, 624) 127 (320, 19) 22.1 (42.8, 4.5)
IDL-p total, nmol/L
Placebo 151 (96, 220) 139 (85, 201) 14 (82, 56) 10.6 (45.3, 49.0)
Rosuvastatin 156 (99, 225) 83 (52, 124) 68 (138, 4) 45.9 (69.4, 4.4)
VLDL size, nm diameter
Placebo 49 (44.3, 53.7) 49.3 (44.6, 55.0) 0.6 (3.7, 5.0) 1.3 (7.3, 10.9)
Rosuvastatin 49 (44.3, 54.1) 50.2 (46.1, 55.1) 1.4 (3.0, 5.9) 2.9 (5.8, 12.7)
VLDL-p by subclass, nmol/L
Total
Placebo 43.8 (30.1, 58.5) 44.1 (30.9, 60.8) 1.2 (10.1, 13) 3.5 (21.8, 35.4)
Rosuvastatin 43.3 (29.9, 58.8) 33.8 (23.5, 46.7) 8.5 (20.4, 3.2) 19.6 (40.5, 10.2)
Large
Placebo 2.8 (1.3, 4.9) 3.0 (1.3, 5.6) 0.2 (1.0, 1.6) 7.7 (35.7, 75.9)
Rosuvastatin 2.8 (1.4, 5.0) 2.2 (1.1, 4.2) 0.3 (1.7, 0.7) 15.4 (50.0, 40.0)
Continued
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lipoprotein measurements. Additionally, a more parsimonious
model was selected through backwards elimination (retention
threshold, P<0.10) starting with all variables in model 2;
discrimination was assessed with Harrell C-index, and the
likelihood ratio test was used to determine if model 2
provided signiﬁcantly improved discrimination over this par-
simonious model. Analyses were performed using SAS version
9.3 (Cary, NC). A 2-tailed P<0.05 was considered statistically
signiﬁcant. The study was approved by a local Institutional
Review Board, and subjects provided informed consent.
Results
Baseline Characteristics
Study participants had a median (25th, 75th percentiles) age
of 66 (60, 71) years, and were 36% female. Except for race/
ethnicity, participants in the current study were generally
representative of those in the original JUPITER trial
(Table 1).10 Median baseline LDL-c was 109 (95, 120) mg/
dL, triglycerides were 119 (87, 169) mg/dL, and hsCRP was
4.10 (2.75, 6.70) mg/L.
Total LDL-p and apoB were strongly correlated at baseline
(Table 2), and LDL-p was the most abundant atherogenic
lipoprotein (Figure 2; Table 3). NMR-measured VLDL/CM
triglyceride was strongly correlated with chemically measured
triglycerides and with large VLDL-p (and progressively less
with medium and small VLDL-p). Calculated remnant choles-
terol was (as expected based on the use of the Friedewald
equation) perfectly correlated with triglyceride (r=1.00),
moderately with apoB, non-HDL-c, and VLDL-c (r=0.48,
0.60, and 0.58, respectively), and not with LDL-c (r=0.01).
Baseline Risk of Incident CVD
Among the 11 984 JUPITER participants, a total of 296 primary
events and 489 expanded end points occurred over a median
follow-upof2.0 (maximum5.0) years, representing27 864 per-
son-years. Among participants in the placebo-allocated arm
(N=6050; 189 events; Figure 3), LDL-c was not associated with
increased risk of the primary end point, but signiﬁcant associ-
ations were observed for non-HDL-c (1.17 [1.01, 1.36]),
triglycerides (1.28 [1.10, 1.48]), and apoB (1.27 [1.09, 1.47]).
For the expanded end point that included all-cause mortality
(291 events; Table 4), associations were generally attenuated
and became nonsigniﬁcant for non-HDL-c and apoB. Tertile
analysis demonstrated a graded increase in risk with increasing
levels of these markers but not LDL-c (Table 5).
For NMR-measured lipoproteins, a signiﬁcant association
was noted for LDL-p and the primary end point (1.19 [1.02,
1.38]) but not for the individual LDL subclasses. Smaller LDL
size was a marker of increased risk, but this was no longer
signiﬁcant after additionally adjusting for LDL-p—as previ-
ously suggested16—and HDL-c.
Conversely, most VLDL-p subfractions, as well as total
VLDL-p and NMR-determined VLDL/CM triglycerides, were
associated with increased risk of the primary (Figure 3) or
expanded (Table 4) end point. The magnitude of this risk
was similar to that of chemically measured triglycerides.
Because VLDL-p subfractions were comparably associated
with increased risk, there was no independent association
for average VLDL particle size. Total NMR-measured VLDL-c
was not signiﬁcantly associated with the primary or
expanded end points at baseline. Overall, when the baseline
analysis was performed in the entire cohort adjusting for
Table 3. Continued
Baseline Year 1† Absolute Change‡ % Change
Medium
Placebo 11.8 (6.8, 18.7) 13.6 (7.6, 22.4) 1.9 (3.2, 8.0) 16.7 (26.7, 86.7)
Rosuvastatin 11.6 (6.8, 18.6) 10.9 (6.5, 17.1) 0.6 (6.0, 4.4) 7.0 (42.9, 52.0)
Small
Placebo 27.1 (17.3, 38.1) 25 (16.3, 36.4) 1.4 (12.0, 9.3) 6.0 (37.8, 43.5)
Rosuvastatin 26.6 (17, 38.5) 19.4 (12.4, 28.0) 6.9 (17.3, 3.0) 26.8 (53.2, 16.4)
VLDL triglycerides, mg/dL
Placebo 62.3 (42.7, 87.7) 64 (44.2, 94.1) 3.1 (12.1, 20.2) 5.6 (18.8, 35.8)
Rosuvastatin 62.3 (43.5, 88.3) 51.6 (36.5, 74.6) 9.0 (25.9, 5.5) 15.2 (35.8, 11.3)
Values obtained from individuals with both baseline and year 1 measurements (n=9222). HDL indicates high-density lipoproteins; IDL, intermediate-density lipoproteins; LDL-c, low-density
lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; NMR, nuclear magnetic resonance; RC,
remnant cholesterol; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low-density lipoprotein particle concentration.
*Median (25th percentile, 75th percentile).
†P values from the Wilcoxon signed-rank test comparing baseline and year-1 values were statistically signiﬁcant (P<0.001) for all, with the exception of triglycerides among the placebo
group (P=0.15).
‡P values from the Wilcoxon rank-sum test comparing the change among the rosuvastatin group with the change among the placebo group were <0.001 for all.
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known randomized statin allocation as a covariable, the
results were similar.
Lipoprotein Subclass Response to Statin Therapy
Rosuvastatin therapy produced large median (25th, 75th
percentile) percentage reductions in LDL-c (49.0 [58.2,
32.8]%), apoB (39.4 [47.6, 26.7]%), and non-HDL-c
(42.7 [51.1, 27.7]%; Figure 4; Table 3) and resulted in
greater reductions in large (57.5 [77.0, 24.4]%) versus
small (22.1 [42.8, 4.5]%) LDL-p. Triglycerides and VLDL-p
subfractions showed smaller, more variable responses to
statin therapy, and many participants had no reduction after a
year of statin therapy.
Residual Risk of CVD
Among participants in the statin-allocated arm with on-statin
measures (N=4386), median LDL-c was 55 mg/dL, and
triglyceride was 102 mg/dL. In this population, standard lipid
and apolipoprotein measures were marginally associated with
risk (73 primary end-point events and 108 expanded end-
point events; Figure 5; Tables 4 and 6), including apoB, non-
HDL-c, and LDL-c.
On statin therapy, each SD increment in total VLDL-p, driven
by the smallest VLDL-p subclass, was associated with residual
risk (Figure 5). Adjusted hazard ratios (95%CIs) per increasing
tertile of on-treatment small VLDL-p were 1.00 (Ref.), 2.29
(1.09, 4.82), and 3.73 (1.86, 7.49), P for trend <0.0001
(Table 6). For each SD greater average VLDL size, reﬂecting a
shift away from small VLDL-p, there was a 40% relative risk
reduction. In sensitivity analyses these associations remained
signiﬁcant after adjustment for other NMR lipoproteins (1.83
[1.35, 2.50]) and incrementally for HDL-c (1.77 [1.29, 2.43]) or
HDL-p (1.78 [1.31, 2.43]). On-treatment NMR-measured VLDL-
c was associated with both the primary and expanded end
points. This risk was driven by the cholesterol contained in the
small VLDL subclass (primary end point 1.74 [1.32, 2.30];
expanded end point 1.59 [1.27, 1.98]). In contrast, no
associations were found for on-treatment triglycerides, NMR-
measured VLDL/CM triglycerides, formulaic remnant choles-
terol, or large and medium VLDL-p subfractions.
Figure 3. Adjusted* HR and 95%CI for the primary incident CVD end point in the JUPITER placebo group
associated with baseline marker levels. ApoB indicates apolipoprotein B; CM, chylomicrons; HR, hazard
ratio; IDL-p, intermediate density lipoprotein particle concentration; JUPITER, Justiﬁcation for the Use of
Statins in Prevention: an Intervention Trial; LDL-c, low-density lipoprotein cholesterol; LDL-p, low-density
lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; RC,
calculated remnant cholesterol; TG, triglycerides; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p,
very low-density lipoprotein particle concentration. *Adjusted for age, sex, race, smoking status, family
history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and
hsCRP. †LDL size was no longer associated with either end point after adjusting for LDL-p and HDL-c. The
following biomarkers were natural-log-transformed: triglyceride, RC, small LDL-p, IDL-p, all VLDL-p
subclasses, VLDL/CM triglycerides, and VLDL-c.
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Secondary Cohort Examination
Participants in CATHGEN with LDL-c <130 mg/dL and
triglycerides <500 mg/dL were demographically similar to
JUPITER participants in age (mean [SD] 60.711.7 years), sex
(62.3% male), and racial (74.2% white) distribution as well as
based on body-mass index (30.17.4 kg/m2) and systolic
blood pressure (14425 mm Hg). Among these 2149 indi-
viduals, 154 events occurred over median (maximum) 5.0
(13.3) years of follow-up. Total VLDL-p was signiﬁcantly
associated with risk of myocardial infarction, driven by the
small VLDL lipoprotein subclass (Table 7). As with larger
VLDL-p subclasses, VLDL/CM triglyceride concentration was
not signiﬁcantly associated with risk. Although restriction to
those conﬁrmed as having a prescribed statin reduced sample
size to only 833 individuals, the pattern of the associations
was unchanged, but the conﬁdence intervals in this much
smaller subgroup were wider and no longer signiﬁcant. When
no LDL-c or statin-based selection criteria were applied, risk
of myocardial infarction among all comers with NMR
measurements in the cohort was not signiﬁcantly associated
with VLDL-p levels. Similarly, the magnitude of risk associated
with LDL-p became larger as the cohort was progressively
more selected based on LDL-c <130 mg/dL and statin
prescription status.
Prediction Model Performance
In JUPITER the C-statistic (a measure of model discrimination)
for the baseline CVD risk model (built with 12 clinical and
standard lipid measure variables; 12 degrees of freedom) for
the placebo group was not signiﬁcantly changed (P=0.50) with
Table 4. Adjusted HR and 95%CI for the Expanded End Point (Incident CVD and All-Cause Mortality) in the Placebo Group at
Baseline and the Rosuvastatin Group On-Treatment
Baseline Risk (Placebo; N=6050) Residual Risk (Rosuvatatin; N=4386)
CVD and All-Cause Death CVD and All-Cause Death
HR per 1 SD Higher* (95%CI) P Value HR per 1 SD Higher*† (95%CI) P Value
Lipids and apolipoproteins (SD), mg/dL
LDL-c 0.90 (0.80, 1.00) 0.061 1.14 (1.02, 1.28) 0.024
Non-HDL-c 1.00 (0.88, 1.12) 0.979 1.16 (1.02, 1.32) 0.023
Apolipoprotein B 1.06 (0.94, 1.19) 0.352 1.19 (1.01, 1.40) 0.033
Triglycerides‡ 1.18 (1.05, 1.33) 0.005 1.10 (0.89, 1.36) 0.391
RC‡ 1.19 (1.05, 1.33) 0.005 1.10 (0.89, 1.37) 0.390
NMR lipoproteins (SD)
LDL size 0.85 (0.75, 0.95) 0.006 1.21 (0.98, 1.50) 0.081
LDL-p
Total 1.01 (0.89, 1.14) 0.923 1.07 (0.88, 1.31) 0.504
Large 0.93 (0.82, 1.05) 0.218 1.18 (0.95, 1.47) 0.144
Small‡ 0.97 (0.86, 1.08) 0.518 0.87 (0.72, 1.05) 0.153
IDL-p‡ 0.98 (0.87, 1.10) 0.746 0.98 (0.83, 1.15) 0.760
VLDL size 1.08 (0.96, 1.21) 0.206 0.72 (0.57, 0.91) 0.005
VLDL-p
Total‡ 1.25 (1.11, 1.41) 0.0003 1.32 (1.08, 1.61) 0.006
Large‡ 1.19 (1.05, 1.35) 0.001 1.03 (0.85, 1.26) 0.762
Medium‡ 1.22 (1.08, 1.39) 0.002 1.04 (0.84, 1.27) 0.741
Small‡ 1.16 (1.04, 1.29) 0.007 1.56 (1.25, 1.95) <0.0001
VLDL/chylomicron triglycerides ‡ 1.27 (1.13, 1.42) <0.0001 1.10 (0.91, 1.34) 0.325
VLDL-c‡ 1.10 (0.95, 1.27) 0.211 1.27 (1.05, 1.54) 0.014
CHD indicates coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IDL, intermediate-density lipoprotein; LDL-c,
low-density lipoprotein cholesterol; LDL-p, low density lipoprotein particle concentration; NMR, nuclear magnetic resonance; non-HDL-c, non-high density lipoprotein cholesterol
concentration; RC, remnant cholesterol; VLDL-c, very low density lipoprotein cholesterol; VLDL-p, very low density lipoprotein particle concentration.
*Adjusted for age, race, sex, race, family history of CHD, smoking, systolic blood pressure, fasting glucose, body mass index, and the natural logarithm of hsCRP.
†Baseline SDs used to allow for comparison.
‡Variable was log-transformed (ln), and risk is per change in SD of the natural log of the variable.
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Table 5. Baseline Lipid and Lipoproteins by Tertile in Relation to End Points in the Placebo Arm
Adjusted HR (95%CI)*
Lowest Tertile Middle Tertile Highest Tertile Ptrend
†
Lipids and apolipoproteins
LDL-c
Range, mg/dL ≤100 100 to 116 >116
Primary end point Ref 0.99 (0.71, 1.14) 1.08 (0.76, 1.55) 0.66
Secondary end point Ref 0.77 (0.59, 1.00) 0.85 (0.64, 1.12) 0.22
Non-HDL-c
Range, mg/dL ≤125 125 to 143 >143
Primary end point Ref 1.18 (0.82, 1.69) 1.33 (0.93, 1.92) 0.122
Secondary end point Ref 0.99 (0.75, 1.31) 1.06 (0.80, 1.41) 0.700
Apolipoprotein B
Range, mg/dL ≤101 101 to 117 >117
Primary end point Ref 1.42 (1.00, 2.05) 1.54 (1.06, 2.22) 0.024
Secondary end point Ref 1.09 (0.83, 1.44) 1.06 (0.79, 1.41) 0.701
Triglycerides
Range, mg/dL ≤96 96 to 147 >147
Primary end point Ref 1.59 (1.08, 2.33) 1.84 (1.26, 2.69) 0.002
Secondary end point Ref 1.40 (1.03, 1.88) 1.57 (1.16, 2.11) 0.003
NMR lipoproteins
LDL size
Range, nm ≤20.7 20.7 to 21.2 >21.2
Primary end point Ref 0.67 (0.47, 0.97) 0.77 (0.54, 1.09) 0.131
Secondary end point Ref 0.67 (0.50, 0.89) 0.72 (0.54, 0.95) 0.019
LDL-p
Total
Range, nmol/L ≤1147 1147 to 1390 >1390
Primary end point Ref 1.38 (0.95, 2.00) 1.57 (1.09, 2.28) 0.017
Secondary end point Ref 1.12 (0.85, 1.48) 1.03 (0.77, 1.38) 0.828
Large
Range ≤364 364 to 557 >557
Primary end point Ref 0.75 (0.52, 1.09) 1.03 (0.73, 1.45) 0.849
Secondary end point Ref 0.76 (0.57, 1.01) 0.90 (0.68, 1.19) 0.466
Small
Range, nmol/L ≤485 485 to 728 >728
Primary end point Ref 1.29 (0.89, 1.88) 1.44 (0.99, 2.10) 0.059
secondary end point Ref 1.13 (0.85, 1.51) 1.14 (0.84, 1.53) 0.402
IDL-p
Range ≤115 115 to 193 >193
Primary end point Ref 1.15 (0.82, 1.63) 0.99 (0.69, 1.42) 0.967
Secondary end point Ref 1.08 (0.82, 1.42) 1.02 (0.76, 1.36) 0.893
Continued
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the addition of all NMR lipoprotein measures (24 variables):
0.664 (95%CI=0.618, 0.710) to 0.668 (0.623, 0.714). A
baseline parsimonious model (which statistically selected
among the 24 candidate variables those that most signiﬁ-
cantly contributed to CVD prediction) identiﬁed age, sex,
smoking, family history, and medium VLDL-p as top predictor
variables. Conversely for residual risk models, discrimination
was signiﬁcantly improved by a model that included all of the
NMR variables (24 degrees of freedom) compared to a model
with only clinical and standard lipid variables (12 degrees of
freedom): C=0.780 (0.718, 0.842) versus 0.712 (0.636,
0.788); P=0.0001. The parsimonious model for residual risk
selected age, sex, smoking, hsCRP, VLDL-c, small LDL-p, and
VLDL size as top predictors.
Discussion
This study was designed to identify circulating lipoproteins
measured by 1H NMR associated with CVD risk among
individuals with naturally or pharmacologically low (<130 mg/
dL) LDL-c. We observed that, among such individuals, risk was
associated with lipoprotein particle concentration, including
LDL and VLDL subfractions. Intriguingly, among individuals on
statin therapy (median LDL-c 55 mg/dL), the lipoprotein
subclass small VLDL-p (and its associated cholesterol)
conferred an 70% per-SD increase in residual risk, corre-
sponding to a 3.7-fold increase in risk among those in the
highest tertile. These observations were extended using a
distinct, diverse cohort referred for cardiac catheterization
Table 5. Continued
Adjusted HR (95%CI)*
Lowest Tertile Middle Tertile Highest Tertile Ptrend
†
VLDL size
Range, nm ≤45.6 45.6 to 51.7 >51.7
Primary end point Ref 1.23 (0.86, 1.77) 1.30 (0.90, 1.88) 0.164
Secondary end point Ref 1.31 (0.99, 1.75) 1.26 (0.93, 1.69) 0.128
VLDL-p
Total
Range, nmol/L ≤34.6 34.6 to 53.2 >53.2
Primary end point Ref 1.14 (0.77, 1.66) 1.55 (1.08, 2.21) 0.014
Secondary end point Ref 1.21 (0.90, 1.64) 1.54 (1.15, 2.05) 0.003
Large
Range, nmol/L ≤1.7 1.7 to 4.0 >4.0
Primary end point Ref 1.45 (1.01, 2.07) 1.26 (0.86, 1.84) 0.246
Secondary end point Ref 1.44 (1.08, 1.93) 1.41 (1.04, 1.90) 0.028
Medium
Range, nmol/L ≤8.1 8.1 to 15.7 >15.7
Primary end point Ref 1.36 (0.92, 2.00) 1.79 (1.24, 2.60) 0.002
Secondary end point Ref 1.18 (0.87, 1.60) 1.72 (1.28, 2.29) 0.0002
Small
Range, nmol/L ≤20.9 20.9 to 34.3 >34.3
Primary end point Ref 1.12 (0.77, 1.62) 1.31 (0.91, 1.86) 0.139
Secondary end point Ref 1.31 (0.97, 1.78) 1.45 (1.08, 1.95) 0.014
VLDL triglycerides
Range, mg/dL ≤49.1 49.1 to 77.5 >77.5
Primary end point Ref 1.30 (0.89, 1.89) 1.49 (1.03, 2.16) 0.035
Secondary end point Ref 1.29 (0.96, 1.75) 1.59 (1.18, 2.13) 0.002
Tertiles derived from the baseline population. HR indicates hazard ratio; hsCRP, high-sensitivity C-reactive protein; IDL-p, intermediate-density particle concentration; LDL-c, low-density
lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; RC, remnant cholesterol; Ref, reference
value; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low-density lipoprotein particle concentration.
*Adjusted for adjusted for age, sex, race, smoking status, family history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP.
†P for nonlinear trend.
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(CATHGEN); as reﬁnement of the population based on LDL-c
<130 mg/dL or statin prescription was undertaken, the
magnitude of risk related to lipoprotein subclasses appeared
ampliﬁed (including small VLDL-p). Exploratory analyses
suggested that on-statin residual risk prediction could be
signiﬁcantly improved beyond known clinical and standard
lipid risk factors with the inclusion of NMR-based VLDL
measurements. Overall, our results suggest a potential role
for VLDL lipoproteins in the development of CVD events,
particularly among individuals with lower LDL-c—a rapidly
growing population in clinical practice1,2 in whom event rates
nonetheless remain unacceptably high.3,17
We observed that baseline apoB and LDL-p were
associated with risk of incident CVD. Although both
measures were highly correlated (r=0.79), the magnitude
of risk associated with apoB was somewhat greater than
that for LDL-p, consistent with ﬁndings from the Women’s
Health Study.14 In addition to LDL, apoB is also present on
VLDL and lipoprotein(a), the latter of which also carried
increased risk in JUPITER.18
Triglycerides and VLDL/CM measures were associated
with risk in the JUPITER placebo group, whereas the small
VLDL-p subclass (but not triglycerides) was strongly associ-
ated with risk in the statin group. VLDL (also referred to as
triglyceride-rich lipoproteins) are believed to confer athero-
genic risk related to their cholesterol content (ie, remnant
cholesterol),19 which can be deposited directly into the
arterial wall without modiﬁcation.20 Why the magnitude of risk
related to VLDL-p appeared to differ based on statin allocation
is unclear and deserves further investigation. It is possible
that statin-related suppression of inﬂammation could modify
the relationship between VLDL and atherosclerosis.19
Our study is novel in its consideration of NMR-based
atherogenic lipoprotein measures among dedicated popula-
tions of individuals with low (<130 mg/dL) LDL-c, an
increasingly prevalent population in the era of LDL-c reduc-
tion. Our ﬁndings support and extend previous observations
from other cohorts, wherein lipoprotein particle concentration
measured by apoB and NMR (LDL-p) was associated with CVD
events among statin-treated secondary prevention individu-
als.21 Additionally, no other study has assessed the signiﬁ-
cance of on-statin levels of NMR-measured VLDL lipoproteins
in relation to residual CVD risk. Our results help frame those
of previous studies, wherein on-statin triglyceride levels have
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Figure 4. Median percentage change in lipids, apoB, and NMR-measured
lipoprotein subclasses in the placebo and statin-treated arms in JUPITER. Error
bars represent 25th and 75th percentiles. CM indicates chylomicrons; IDL-p,
intermediate-density lipoprotein particle concentration; JUPITER, Justiﬁcation
for the Use of Statins in Prevention: an Intervention Trial; LDL-c, low-density
lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration;
NMR, nuclear magnetic resonance; non-HDL-c, non-high-density lipoprotein
cholesterol concentration; RC, calculated remnant cholesterol; TG, triglyc-
erides; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low
density lipoprotein particle concentration.
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been inconsistently associated with residual risk,22 suggest-
ing the need for more detailed VLDL phenotyping. Our results
also support and extend recent efforts to more comprehen-
sively proﬁle statin effects on the spectrum of the lipid and
lipoprotein milieu.23
The risk estimates observed with NMR are largely in
agreement with those recently obtained in the same cohort
using electrospray ion mobility,24 except that stronger
association was noted for NMR-measured small VLDL-p with
residual risk. In JUPITER, measurements of small VLDL by
NMR and ion mobility were only modestly correlated (Spear-
man r=0.22). In other cohorts, NMR and ion mobility have also
demonstrated differential resolution of the proatherogenic
effects of VLDL.25 The basis for such differences may be due
to methodological differences, with NMR providing better
measurement of lipid-rich lipoprotein particles such as VLDL,
while ion mobility may better capture protein-rich particles.
Our study has several potential limitations. First, the
follow-up duration in JUPITER was relatively short for a
primary prevention study (due to early termination of the trial
for beneﬁt by the Data Safety and Monitoring Board).
Nonetheless, event rates were sufﬁciently high to detect a
number of expected and novel associations, and the longer
follow-up in CATHGEN (median [maximum] 5.0 [13.3] years)
suggested longitudinal extrapolation of these results.
Second, all JUPITER study participants had elevated hsCRP.
Systemic inﬂammation has been shown to affect the
composition of the lipoprotein milieu, including VLDL.26 At
a minimum, it has been estimated that more than 1 in 50
adult Americans would meet the JUPITER inclusion criteria.27
Furthermore, hsCRP was not part of the selection criteria in
CATHGEN, suggesting that these ﬁndings may be more
broadly generalizable. Finally, multiple comparisons were
performed, increasing the chance of a type I error. However,
examination of an independent cohort supported the key
associations observed, and the ﬁndings are supported by
prior biologic and epidemiological studies. Nonetheless,
given the multiplicity of hypotheses tested, these results
should be viewed as hypothesis-generating and require
further validation in additional cohorts.
Figure 5. On-statin adjusted* HR and 95%CI for the primary incident CVD end point in the JUPITER
rosuvastatin 20-mg group. CM indicates chylomicrons; HR, hazard ratio; IDL-p, intermediate-density
lipoprotein particle concentration; JUPITER, Justiﬁcation for the Use of Statins in Prevention: an Intervention
Trial; LDL-c, low-density lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-
HDL-c, non-high-density lipoprotein cholesterol concentration; RC, calculated remnant cholesterol; SD,
standard deviation; TG, triglycerides; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low-
density lipoprotein particle concentration. *Adjusted for age, sex, race, smoking status, family history of
premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP. The
following biomarkers were natural-log-transformed: triglyceride, RC, small LDL-p, IDL-p, all VLDL-p
subclasses, VLDL/CM triglycerides, and VLDL-c.
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Table 6. On-Treatment Lipid and Lipoproteins by Tertile in Relation to End Points in the Rosuvastatin Arm
Adjusted HR (95%CI)*
Lowest Tertile Middle Tertile Highest Tertile Ptrend
†
Lipids and apolipoproteins
LDL-c
Range, mg/dL ≤47 47 to 63 >63
Primary end point Ref 0.74 (0.39, 1.42) 1.73 (1.00, 2.98) 0.034
Secondary end point Ref 0.69 (0.41, 1.17) 1.41 (0.91, 2.21) 0.099
Non-HDL-c
Range, mg/dL ≤68 68 to 87 >87
Primary end point Ref 0.80 (0.43, 1.49) 1.53 (0.89, 2.63) 0.111
Secondary end point Ref 0.81 (0.48, 1.34) 1.60 (1.02, 2.50) 0.030
Apolipoprotein B
Range, mg/dL ≤60 60 to 75 >75
Primary end point Ref 0.99 (0.54, 1.80) 1.47 (0.83, 2.58) 0.169
Secondary end point Ref 0.95 (0.57, 1.58) 1.55 (0.98, 2.47) 0.049
Triglycerides
Range, mg/dL ≤85 85 to 122 >122
Primary end point Ref 0.98 (0.55, 1.74) 1.04 (0.59, 1.85) 0.883
Secondary end point Ref 1.05 (0.65, 1.68) 1.17 (0.73, 1.88) 0.506
NMR lipoproteins
LDL size
Range, nm ≤20.3 20.3 to 20.8 >20.8
Primary end point Ref 0.75 (0.40, 1.40) 1.58 (0.91, 2.72) 0.100
Secondary end point Ref 0.74 (0.44, 1.25) 1.48 (0.94, 2.32) 0.078
LDL-p
Total
Range, nmol/L ≤678 678 to 879 >879
Primary end point Ref 0.96 (0.54, 1.71) 1.09 (0.61, 1.92) 0.772
Secondary end point Ref 0.74 (0.45, 1.22) 1.14 (0.73, 1.79) 0.528
Large
Range ≤117 117 to 246 >246
Primary end point Ref 1.34 (0.75, 2.39) 1.38 (0.76, 2.50) 0.296
Secondary end point Ref 1.03 (0.64, 1.68) 1.28 (0.80, 2.06) 0.291
Small
Range, nmol/L ≤415 415 to 572 >572
Primary end point Ref 0.69 (0.40, 1.22) 0.63 (0.36, 1.13) 0.117
Secondary end point Ref 0.69 (0.43, 1.11) 0.81 (0.51, 1.28) 0.361
IDL-p
Range ≤62 62 to 106 >106
Primary end point Ref 0.80 (0.48, 1.36) 0.49 (0.27, 0.91) 0.024
Secondary end point Ref 0.79 (0.50, 1.23) 0.67 (0.42, 1.07) 0.090
Continued
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Conclusions
In conclusion, among individuals with low (<130 mg/dL) LDL-
c, risk remains associated with lipoprotein particle concen-
tration, including VLDL lipoproteins. We observed on-statin
risk strongly associated with small VLDL-p—risk that appears
to be triglyceride-independent and instead related to the
cholesterol carried by these small VLDL particles. Overall,
these hypothesis-generating ﬁndings draw attention to the
potential importance of VLDL lipoproteins, in particular small
remnant particles, which are associated with risk but are
currently not the target of prediction or therapeutic interven-
tion. Additional studies are needed to validate these ﬁndings
and assess the potential causal role of these lipoproteins as
determinants of CVD risk.
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Adjusted HR (95%CI)*
Lowest Tertile Middle Tertile Highest Tertile Ptrend
†
VLDL size
Range, nm ≤47.4 47.4 to 53.1 >53.1
Primary end point Ref 0.83 (0.50, 1.38) 0.31 (0.15, 0.63) 0.002
Secondary end point Ref 0.81 (0.53, 1.23) 0.40 (0.23, 0.70) 0.001
VLDL-p
Total
Range, nmol/L ≤27.0 27.0 to 41.3 >41.3
Primary end point Ref 1.40 (0.75, 2.61) 1.67 (0.92, 3.04) 0.095
Secondary end point Ref 1.29 (0.78, 2.14) 1.59 (0.98, 2.58) 0.059
Large
Range, nmol/L ≤1.4 1.4 to 3.3 >3.3
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Tertiles derived from on-treatment (rosuvastatin) group at 12 months. HR indicates hazard ratio; hsCRP, high-sensitivity C-reactive protein; IDL-p, intermediate-density particle
concentration; LDL-c, low-density lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; RC,
remnant cholesterol; Ref, reference value; VLDL-c, very low density lipoprotein cholesterol; VLDL-p, very low density lipoprotein particle concentration.
*Adjusted for adjusted for age, sex, race, smoking status, family history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP.
†P for nonlinear trend.
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